Browse the evidence

Multidisciplinary therapy combining nutritional, physical, and behavioral interventions reduces body weight, fat mass, and cardiometabolic risk factors in adults with obesity.

To manage obesity effectively, you need a team approach that includes diet, exercise, and behavioral counseling, rather than just one of these. Aim for sessions 2-3 times a week, lasting at least 20 minutes, over a period of weeks to months. This combined approach helps reduce weight and fat while preserving muscle and improving metabolic health, which is crucial for long-term success.

Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.

Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.

Aerobic and resistance exercise reduce hepatic steatosis and improve insulin sensitivity in MASLD patients independently of significant body weight loss.

You do not need to lose weight to improve your liver health through exercise. Both aerobic exercise (45-60 minutes, 3-5 times a week) and resistance training (3 times a week for 8-12 weeks) can significantly reduce liver fat and improve insulin sensitivity, even if your body weight remains stable. Focus on consistency and metabolic health rather than just the number on the scale.

Tirzepatide (TZP) produces significantly greater weight loss than semaglutide (SEM) in patients with rheumatic and musculoskeletal diseases (RMDs), with TZP users losing 8.2% of body weight compared to 5.8% for SEM users at 12 months.

If you have a rheumatic condition and are using GLP-1 medications, Tirzepatide is associated with greater weight loss than Semaglutide. In this large study, Tirzepatide users lost 8.2% of their body weight at 12 months, compared to 5.8% for Semaglutide users. This benefit was observed even in patients with mobility limitations, suggesting that pharmacological intervention can overcome some barriers to weight loss in this population.

High-intensity resistance exercise (RE) is the primary non-pharmacological intervention for preventing and treating osteosarcopenia, as it simultaneously increases lean body mass, strength, and bone mineral density (BMD), whereas daily activities and cardiovascular exercises are insufficient for stimulating osteoblastogenesis.

To fight osteosarcopenia, you must lift heavy weights. Walking and swimming are healthy but will not build bone density. Focus on high-intensity resistance exercises, ideally combined with adequate protein, creatine, and vitamin D intake. Consult a professional to ensure safety, especially if you have existing bone fragility.

The effectiveness of protein supplementation on lean mass and strength is significantly higher in sarcopenic and frail older adults compared to overweight or obese older adults.

If you are an older adult who is frail, sarcopenic, or institutionalized, adding protein supplements to your resistance training is more likely to help you build lean mass and strength. If you are overweight or obese, you may not see these benefits, as your body's response to protein may be blunted by excess weight and lower activity levels.

Resistance exercise training (RET) volume is the primary driver of skeletal muscle hypertrophy, with higher weekly volumes yielding greater muscle growth up to a specific threshold.

To maximize muscle growth, focus on increasing your total training volume (sets x reps x weight) over time. You do not need to lift extremely heavy weights; moderate loads work just as well if you train close to failure. However, be aware that there is a limit to how much volume you can handle before gains stall or health suffers, so find your personal threshold.

Dietary protein intake supports but does not independently drive skeletal muscle hypertrophy; its primary role is to amplify the anabolic response to resistance exercise.

Eat enough protein (1.2-1.6 g/kg/day) to support your training, but do not expect it to build muscle on its own. The key to muscle growth is resistance exercise. Protein helps maximize the gains you get from your workouts.

Protein and essential amino acid (EAA) supplementation promotes measurable muscle hypertrophy (via ultrasound/MRI) only when daily intake is below 1.6 g/kg/day or per-meal leucine is below 2–3 g; benefits plateau once these thresholds are met.

If you already eat enough protein (around 1.6g per kg of body weight) or get enough leucine per meal (2-3g), adding more protein powder will not make your muscles grow bigger. Focus on hitting that baseline first; extra protein is wasted for hypertrophy purposes.

Creatine monohydrate (3–5 g/day) increases muscle thickness and cross-sectional area in resistance training interventions lasting 8–12 weeks or more, primarily by enabling higher training volume and quality rather than direct anabolic signaling.

Take 3-5g of creatine monohydrate daily. It won't magically build muscle overnight, but it will help you lift more volume over 8-12 weeks, which leads to actual muscle growth. Don't expect results in the first few weeks.

Female endurance athletes unintentionally underfuel with carbohydrates relative to training volume, creating a cumulative energy deficit, while simultaneously prioritizing protein intake to meet or exceed recommendations.

Female endurance athletes should prioritize carbohydrate intake on training days to match volume, as deficits increase significantly with higher loads. Do not neglect rest days; even low-intensity sessions require adequate fuel to prevent cumulative energy deficits. While protein intake is often correctly prioritized, ensure it does not displace necessary carbohydrates. Address psychological barriers like body image and time constraints by planning simple, accessible carbohydrate sources for all training days, not just hard sessions.

Structured, individualized nutritional interventions significantly improve sport-specific performance and increase energy availability in competitive female athletes compared to generic guidance.

If you are a competitive female athlete, generic advice is likely not enough. You need a personalized plan that targets at least 45 kcal per kg of fat-free mass daily. Focus on consuming 5-8g of carbs and 1.6-2.0g of protein per kg of body weight. Work with a professional to adjust this gradually to avoid psychological resistance, and monitor your energy availability regularly to ensure you are not in a deficit.

Individualized nutritional interventions significantly reduce the prevalence of Female Athlete Triad risk (LEAF-Q ≥ 8) in competitive female athletes.

If you are at risk for the Female Athlete Triad, screening alone is not enough. You need a structured nutritional plan that increases your energy availability to at least 45 kcal/kg of fat-free mass daily. This involves eating enough carbohydrates and protein to support your training load, monitored by a professional to ensure you are not in a deficit.

Individualized nutritional interventions significantly improve nutritional knowledge and reduce eating disorder risk behaviors (EDE-Q) in competitive female athletes.

To improve your nutritional knowledge and reduce risky eating behaviors, seek a structured educational program that is part of a larger individualized plan. This should include 6 sessions covering energy availability, carbohydrates, and recovery, tailored to your specific sport and needs.

Incretin receptor agonists (GLP-1RA, dual/triple agonists) and SGLT2 inhibitors reduce the risk of progression to type 2 diabetes and improve cardiovascular outcomes in patients with prediabetes, primarily through weight loss and reduction of visceral ectopic fat.

If you have prediabetes along with obesity, heart failure, or kidney disease, your doctor may consider newer medications like GLP-1 agonists (e.g., semaglutide) or SGLT2 inhibitors. These drugs help with weight loss and reduce cardiovascular risk. They are not yet first-line for all prediabetes patients due to cost and lack of formal indications, but they can be very effective for high-risk individuals.

Intensive lifestyle interventions (ILIs) targeting fat reduction (specifically visceral and body fat mass) significantly improve complete remission rates in overweight patients undergoing fertility-sparing treatment for endometrial cancer and intraepithelial neoplasia.

For overweight patients undergoing fertility-sparing treatment for endometrial precancer, intensive lifestyle changes focusing on fat loss (not just scale weight) significantly improve remission rates. This involves a caloric deficit, daily moderate aerobic exercise, and resistance training to protect muscle mass. Aim for a modest ~3% weight loss, as excessive loss may reduce efficacy by depleting muscle.

Lifestyle interventions during OMM treatment should shift focus from caloric deficit for weight loss to optimizing health, specifically by mitigating lean mass loss through high protein intake and resistance training.

While taking OMMs, prioritize consuming 1.5g of protein per kg of fat-free mass (or 80-120g daily) and engage in resistance training 2-3 times per week. This helps preserve muscle mass and strength, which can be lost during rapid weight loss, and supports overall physical function.

A very low carbohydrate-low protein (VLCLP) diet is the most effective macronutrient ratio for weight loss compared to a moderate fat-low protein (MFLP) control diet, achieving a mean weight loss of 4.10 kg.

If your primary goal is weight loss, a diet very low in carbohydrates (≤30% of calories) and low in protein (≤30% of calories) appears more effective than high-protein low-carb diets. This approach outperforms standard moderate-fat diets. Ensure you are overweight or obese, as results in normal-weight individuals are not well-established.

Treatment-resistant type 2 diabetes, defined as failure to achieve HbA1c targets despite triple oral therapy (metformin, sulfonylurea, and a third agent), can be effectively managed by adding a DPP-4 inhibitor and an SGLT2 inhibitor to metformin, or by combining basal insulin with a GLP-1 receptor agonist or SGLT2 inhibitor.

If your blood sugar remains high despite taking three oral diabetes medications (metformin, a sulfonylurea, and another), ask your doctor about adding a DPP-4 inhibitor and an SGLT2 inhibitor. These oral drugs work together to lower blood sugar effectively. If you are already on insulin, adding a GLP-1 receptor agonist or an SGLT2 inhibitor can improve control, reduce insulin dosage, and help with weight loss without increasing hypoglycemia risk.

Replacing saturated fatty acids (SFAs) with polyunsaturated fatty acids (PUFAs) reduces the risk of coronary events and mortality, whereas replacing SFAs with carbohydrates increases risk.

Don't just cut fat; swap the right kind. Replace saturated fats (found in palm, coconut, dairy) with polyunsaturated fats (found in fish, flax, sunflower oils). Avoid replacing them with refined carbs, as that increases heart disease risk.

Low-carbohydrate diets can induce remission of type 2 diabetes, with clinical trials showing >50% remission rates in some studies.

If you have type 2 diabetes, a ketogenic diet (20-50g carbs/day) can potentially lead to remission. Work with your doctor to monitor blood sugar and adjust medications, as many patients reduce or stop medications within weeks.

Obesity causes secondary hormonal changes (elevated TSH, insulin/leptin resistance) that mimic hypothyroidism; weight loss alone can normalize these hormone levels without thyroid medication.

If you are obese and have slightly high TSH, it might be because of your weight, not a broken thyroid. Losing weight can often fix these hormone levels without medication. Ask your doctor if your thyroid issue is 'secondary' to obesity.

GLP-1 receptor agonists (e.g., tirzepatide) and bariatric surgery are highly effective for weight loss in patients with thyroid disease and should be considered when behavioral therapy fails, as they do not increase thyroid cancer risk in non-MTC patients.

If diet and exercise aren't enough, GLP-1 drugs or surgery are safe and effective options even if you have thyroid disease (unless you have a specific family history of thyroid cancer). These treatments cause significant weight loss (5-20%+) and improve cardiovascular health.

Bariatric surgery, specifically Roux-en-Y gastric bypass, resolves non-alcoholic steatohepatitis (NASH) in approximately 85% of patients and regresses liver fibrosis, outperforming conservative lifestyle interventions.

For obese patients with fatty liver disease who have not achieved results with diet and exercise, Roux-en-Y gastric bypass is a highly effective treatment that can resolve NASH in the majority of cases and reverse fibrosis. It should be considered before liver damage becomes irreversible (cirrhosis).